Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Share this content:
Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.
Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

Veliparib added to cisplatin and etoposide improves progression-free survival (PFS) among patients with extensive stage small-cell lung cancer (ES-SCLC), according to data from the ECOG-ACRIN 2511 study (ClinicalTrials.gov Identifier: NCT01642251) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

Data were presented by Taofeek Kunle Owonikoko, MD, PhD, of the Winship Cancer Institute of Emory University in Atlanta, Georgia.

Veliparib, a potent inhibitor of poly ADP ribose polymerase (PARP), was shown to potentiate the effects of standard therapy in preclinical studies.

In ECOG-ACRIN 2511, patients with ES-SCLC received 4 cycles of cisplatin and etoposide with veliparib 100 mg twice daily on days 1 to 7 or matching placebo. Patients received a maximum of 4 cycles of therapy.

One hundred and twenty-eight patients were enrolled. Equal numbers (64) of patients were randomly assigned to each arm.

Median PFS was 6.1 months for patients receiving veliparib and 5.5 months for patients receiving placebo. With an unadjusted hazard ratio (HR) of 0.75, patients on veliparib were at a 25% reduced risk for progression.

Median overall survival (OS) was 10.3 months for patients on veliparib and 8.9 months for patients on placebo.

Grade 3 to 4 adverse events were, however, more common among patients receiving veliparib.

RELATED: Adjuvant Statins Provide No Benefit in SCLC

“[The study] signals potential benefit of veliparib when added to platinum doublet chemotherapy in patients with extensive stage SCLC. A biomarker enrichment strategy will be needed in order to optimize the benefit of PARP inhibition as a therapeutic strategy in this patient population,” Dr Owonikoko concluded.

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Owonikoko TK, Dahlberg SE, Sica G, et al. Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2017;34(suppl; abstr 8505).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs